HLA DR antigens and gold toxicity

Area of Science:

• Immunogenetics
• Rheumatology
• Pharmacogenetics

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Gold therapy has been used for RA treatment.
• Human Leukocyte Antigen (HLA) DR antigens are associated with immune responses and drug reactions.

Purpose of the Study:

• To investigate the association between HLA DR antigens and adverse reactions to gold therapy in rheumatoid arthritis patients.
• To identify specific HLA DR types that may predict risk for side effects during gold treatment.

Main Methods:

• A cohort of 132 rheumatoid arthritis patients treated with gold was analyzed.
• Patients were genotyped for HLA DR antigens.
• Frequencies of adverse reactions were compared between different HLA DR antigen groups.

Main Results:

• Patients with the HLA DR3 antigen showed a significantly higher frequency of adverse reactions to gold therapy compared to those without DR3.
• HLA DR3-positive patients had an 11-fold increased risk of developing proteinuria.
• The lowest incidence of side effects was observed in patients positive for HLA DR7.
• No significant differences in skin eruptions, liver reactions, or leucopenia were found across DR antigen groups.

Conclusions:

• HLA DR3 is a significant risk factor for adverse reactions, particularly proteinuria, during gold therapy for rheumatoid arthritis.
• HLA DR7 may be associated with a lower risk of side effects.
• HLA DR genotyping could aid in predicting and managing gold therapy-related adverse events in RA patients.